Literature DB >> 20004949

Interstitial inflammation in Alport syndrome.

Jan Jedlicka1, Afschin Soleiman, Dan Draganovici, Jana Mandelbaum, Urs Ziegler, Heinz Regele, Rudolf P Wüthrich, Oliver Gross, Hans-Joachim Anders, Stephan Segerer.   

Abstract

The Alport syndrome is a hereditary glomerular disease linked to structural abnormalities of collagen IV. In a mouse model of Alport syndrome, the interstitial lymphocyte influx was important for disease progression. CXCR3 is a chemokine receptor involved in lymphocyte recruitment to the kidney. We hypothesized that CXCR3-positive T cells might be involved in human Alport syndrome. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded biopsies from 17 patients with Alport syndrome, 10 with immunoglobulin A (IgA) nephropathy, and 11 healthy donor kidneys. We investigated the expression of the alpha5 chain of collagen IV to confirm the morphologic diagnosis, the chemokine receptor CXCR3 and CD3-positive T cells. Alport syndrome biopsies demonstrated a complete loss of the alpha5 chain of collagen IV from the glomerular basement membrane and the morphologic features consistent with Alport syndrome on electron microscopy. A prominent number of CXCR3-positive cells were found in the tubulointerstitium. Most of the CXCR3-positive cells were CD3-positive T cells, demonstrated by double-labeling in selected biopsies. The number of CXCR3-positive cells in kidneys with Alport syndrome correlated with serum creatinine (P < .05) and with morphologic features of a progressive disease (eg, interstitial fibrosis, glomerulosclerosis, and tubular atrophy). The severity of interstitial CXCR3-positive cell influx was similar in Alport syndrome as compared to immunoglobulin A nephropathy. The noninflammatory glomerular lesion of Alport syndrome is associated with prominent interstitial accumulation of CD3- and CXCR3-positive lymphocytes. The degree of infiltration correlated with renal function. We speculate that targeting T lymphocytes, for example, by CXCR3 blocking agents, might be a novel approach to inhibit disease progression in patients with Alport syndrome. Copyright 2010 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004949     DOI: 10.1016/j.humpath.2009.08.024

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.

Authors:  Fangrui Ding; Larysa Wickman; Su Q Wang; Yanqin Zhang; Fang Wang; Farsad Afshinnia; Jeffrey Hodgin; Jie Ding; Roger C Wiggins
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

2.  Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis.

Authors:  Kontheari Sen; Maja T Lindenmeyer; Ariana Gaspert; Felix Eichinger; Matthias A Neusser; Matthias Kretzler; Stephan Segerer; Clemens D Cohen
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

Review 3.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

4.  Periostin: a matricellular protein involved in peritoneal injury during peritoneal dialysis.

Authors:  Niko Braun; Kontheari Sen; M Dominik Alscher; Peter Fritz; Martin Kimmel; Johann Morelle; Eric Goffin; Achim Jörres; Rudolf P Wüthrich; Clemens D Cohen; Stephan Segerer
Journal:  Perit Dial Int       Date:  2013-02-01       Impact factor: 1.756

5.  Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.

Authors:  Glenn M Chertow; Gerald B Appel; Sharon Andreoli; Sripal Bangalore; Geoffrey A Block; Arlene B Chapman; Melanie P Chin; Keisha L Gibson; Angie Goldsberry; Kazumoto Iijima; Lesley A Inker; Bertrand Knebelmann; Laura H Mariani; Colin J Meyer; Kandai Nozu; Megan O'Grady; Arnold L Silva; Peter Stenvinkel; Roser Torra; Bradley A Warady; Pablo E Pergola
Journal:  Am J Nephrol       Date:  2021-03-31       Impact factor: 3.754

6.  Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndrome.

Authors:  Tomoaki Koga; Yukari Kai; Ryosuke Fukuda; Saori Morino-Koga; Mary Ann Suico; Kosuke Koyama; Takashi Sato; Tsuyoshi Shuto; Hirofumi Kai
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

7.  Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing.

Authors:  Hans-Joachim Anders
Journal:  Organogenesis       Date:  2012-04-01       Impact factor: 2.500

8.  Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment.

Authors:  Munkyung Kim; Alessandro Piaia; Neeta Shenoy; David Kagan; Berangere Gapp; Benjamin Kueng; Delphine Weber; William Dietrich; Iwona Ksiazek
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

Review 9.  Danger control programs cause tissue injury and remodeling.

Authors:  Jan H Hagemann; Holger Haegele; Susanna Müller; Hans-Joachim Anders
Journal:  Int J Mol Sci       Date:  2013-05-28       Impact factor: 5.923

10.  RNA-seq of serial kidney biopsies obtained during progression of chronic kidney disease from dogs with X-linked hereditary nephropathy.

Authors:  Candice P Chu; Jessica A Hokamp; Rachel E Cianciolo; Alan R Dabney; Candice Brinkmeyer-Langford; George E Lees; Mary B Nabity
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.